{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113762.1.4.1131.17",
  "meta" : {
    "versionId" : "5",
    "lastUpdated" : "2023-12-21T17:43:03.000-05:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueString" : "CAP Author"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2024-06-03"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2020-11-11"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1131.17",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113762.1.4.1131.17"
    }
  ],
  "version" : "20201111",
  "name" : "GenomicSequenceAnalysisPanel",
  "title" : "Genomic Sequence Analysis Panel",
  "status" : "retired",
  "experimental" : false,
  "date" : "2020-11-11T01:00:26-05:00",
  "publisher" : "CAP Steward",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "US"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis and RNA analysis when performed),(Data Element Scope: CPT Codes for targeted genomic sequence analysis panels, any number of genes >5),(Inclusion Criteria: Genomic sequence analysis panels, any genes, any number of genes > 5),(Exclusion Criteria: Analysis of individual genes; non-solid organ neoplasms (ie blood cancers))",
  "compose" : {
    "include" : [
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "concept" : [
          {
            "code" : "81445",
            "display" : "Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, and RNA analysis when performed, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, NRAS, MET, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed"
          },
          {
            "code" : "81455",
            "display" : "Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm, DNA analysis, and RNA analysis when performed, 51 or greater genes (eg, ALK, BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NPM1, NRAS, MET, NOTCH1, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed"
          }
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:ea392168-23b7-41e6-b2fa-e0502e2dbcec",
    "timestamp" : "2024-06-14T11:35:25-04:00",
    "total" : 2,
    "contains" : [
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "81445",
        "display" : "Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed; DNA analysis or combined DNA and RNA analysis"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "81455",
        "display" : "Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; DNA analysis or combined DNA and RNA analysis"
      }
    ]
  }
}
